Literature DB >> 28922863

Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?

Riccardo Soffietti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28922863      PMCID： PMC5596173          DOI： 10.1093/neuonc/nox146

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  10 in total

1.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.

Authors:  Andrew B Lassman; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M DeAngelis; Suresh C Jhanwar; Marc K Rosenblum; Katherine S Panageas
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

2.  Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.

Authors:  Christina K Speirs; Joseph R Simpson; Clifford G Robinson; Todd A DeWees; David D Tran; Gerry Linette; Michael R Chicoine; Ralph G Dacey; Keith M Rich; Joshua L Dowling; Eric C Leuthardt; Gregory J Zipfel; Albert H Kim; Jiayi Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis.

Authors:  Nimish A Mohile; Peter Forsyth; Douglas Stewart; Jeffrey J Raizer; Nina Paleologos; Tarun Kewalramani; David N Louis; J Gregory Cairncross; Lauren E Abrey
Journal:  J Neurooncol       Date:  2008-05-06       Impact factor: 4.130

5.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

6.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

Authors:  Martin J van den Bent; Alba A Brandes; Martin J B Taphoorn; Johan M Kros; Mathilde C M Kouwenhoven; Jean-Yves Delattre; Hans J J A Bernsen; Marc Frenay; Cees C Tijssen; Wolfgang Grisold; László Sipos; Roelien H Enting; Pim J French; Winand N M Dinjens; Charles J Vecht; Anouk Allgeier; Denis Lacombe; Thierry Gorlia; Khê Hoang-Xuan
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

7.  Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.

Authors:  Manmeet S Ahluwalia; Hao Xie; Saurabh Dahiya; Nooshin Hashemi-Sadraei; David Schiff; Paul G Fisher; Marc C Chamberlain; Susan Pannullo; Herbert B Newton; Cathy Brewer; Laura Wood; Richard Prayson; Paul Elson; David M Peereboom
Journal:  J Neurooncol       Date:  2014-12-23       Impact factor: 4.130

8.  Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors.

Authors:  Esther J J Habets; Martin J B Taphoorn; Sylvie Nederend; Martin Klein; Daniel Delgadillo; Khê Hoang-Xuan; Andrew Bottomley; Anouk Allgeier; Tatjana Seute; Anja M M Gijtenbeek; Jan de Gans; Roelien H Enting; Cees C Tijssen; Martin J van den Bent; Jaap C Reijneveld
Journal:  J Neurooncol       Date:  2013-10-26       Impact factor: 4.130

9.  Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Authors:  Wolfgang Wick; Patrick Roth; Christian Hartmann; Peter Hau; Makoto Nakamura; Florian Stockhammer; Michael C Sabel; Antje Wick; Susanne Koeppen; Ralf Ketter; Peter Vajkoczy; Ilker Eyupoglu; Rolf Kalff; Torsten Pietsch; Caroline Happold; Norbert Galldiks; Friederike Schmidt-Graf; Michael Bamberg; Guido Reifenberger; Michael Platten; Andreas von Deimling; Christoph Meisner; Benedikt Wiestler; Michael Weller
Journal:  Neuro Oncol       Date:  2016-07-01       Impact factor: 12.300

10.  Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma.

Authors:  Alissa A Thomas; Lauren E Abrey; Robert Terziev; Jeffrey Raizer; Nina L Martinez; Peter Forsyth; Nina Paleologos; Matthew Matasar; Craig S Sauter; Craig Moskowitz; Stephen D Nimer; Lisa M DeAngelis; Thomas Kaley; Sean Grimm; David N Louis; J Gregory Cairncross; Katherine S Panageas; Samuel Briggs; Geraldine Faivre; Nimish A Mohile; Jayesh Mehta; Philip Jonsson; Debyani Chakravarty; Jianjiong Gao; Nikolaus Schultz; Cameron W Brennan; Jason T Huse; Antonio Omuro
Journal:  Neuro Oncol       Date:  2017-10-01       Impact factor: 12.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.